Dr Jeff Patton: Biosimilars and OCM

Jeff Patton, MD, president and CEO of Tennessee Oncology, discusses how biosimilars fit into the Oncology Care Model (OCM).

Transcript:

Do you see biosimilars having a role to play in [the Oncology Care Model, OCM]?

I do, and I don’t think we know yet how much cost savings will be involved with biosimilars, but we know it will be some. I think it will start around 15% and go up to 30%, maybe more. I think that the experience in Europe is 30%, 50% is high. The biosimilars are in a space that- so Genentech is biosimilars and is going to be impacted by biosimilars, so about a third of our spend is Genentech products, so if you reduce a third of your spend even by 10%, 15%, 20%, it’s a big number. So, we see biosimilars being very key to saving in OCM.

Related Videos
Michael Kleinrock
Ian Henshaw
Ian Henshaw
Ryan Haumschild, PharmD
John Gabrielson
Ryan Haumschild, PharmD, MS, MBA
Ryan Haumdschild, PharmD
banner for the ophthalmology linkedin live event sponsored by the samsung bioepis in partnership with the center for biosimilars
Ryan Haumschild, PharmD
Nabil Saba
Related Content
© 2023 MJH Life Sciences

All rights reserved.